source
- Zymeworks CEO on why the Theravance deal is value for moneyOn the face of it, nearly $1 billion seems like a lot to spend on a biotech like Theravance. The company was clearly running out of steam, having twice downsized and been hit with repeated ...Endpoints · 1mo ago↗ source
- BioCryst ends internal discovery programs, will close Alabama research facilityBioCryst Pharmaceuticals is winding down its own drug discovery work, saying that it plans to look for future drug programs externally. The company announced a plan to discontinue its internal disc…Endpoints · 1mo ago↗ source
- Evommune's lead drug fails in chronic hives, stock sinksEvommune's shares {$EVMN} fell more than 30% on Monday morning after the biotech reported its first major trial readout since going public last year. In chronic spontaneous urticaria, a skin condit…